Clinical Trial Search

Primary: The Composite Incidence of Death and Non-coronary Artery Bypass Graft (CABG) Major Bleeding — 5.1; 8.5 percentage of participants — p=0.0014

Primary: Number of Participants With First Occurrence of Any Component of Composite MACE (CV Death, MI, or Stroke) — 439; 472 Participants — p=0.121

Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 30.57 score on a scale

Primary: Low Density Lipoprotein - Cholesterol — -6.74; 0.53 mg/dL — p=0.27

Primary: Rates of Major Cardiac Events (AMI or Cardiac Death) Within 30 Days — 0; 0; 0; 10 Participants

Primary: Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), or Stroke — 10.06; 24.64; 10.96; 24.13 percentage of…

Primary: Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke — 864; 1014 Participants

Primary: Percent Change in LDL-Cholesterol — -68.78; -27.58 percent change

Primary: All-cause Death or Subsequent Non-fatal Type 1 or Type 4b MI at One Year Measured as Time to First Such Event. — 51; 53 Participants

Primary: Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™ — 98.4; 257.5 PRU…

Primary: Acceptability as Measured by the Acceptability of Intervention Measure (AIM) — 4.82 score on a scale

Primary: Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out. — 9.3; 10.0…

Primary: Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Treatment Period- Treated Participants With Placebo or…

Primary: Adherence to Refills and Medications Scale (ARMS) — 12.03; 12.18 units on a scale

Primary: Total Mortality. — 138 Participants.

Primary: The Sensitivity and Specificity of ECG for Acute Coronary Occlusion. — 767; 282; 16 Participants

Primary: Sensitivity, Specificity of Detecting Myocardial Ischemia (Reader 1) — 75.2; 67.7 % (n/N)

Primary: Number of Patients With Major Adverse Cardiac Event — 42; 0; 437; 123 Participants

Primary: Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events (Primary Safety) — 36; 17; 109; 43 Patients

Primary: Number of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding…

Primary: Change in LDL-Cholesterol — -70.59; -44.78 percent change mg/dL — p=.0001

Primary: Composite of Death, Myocardial (re-) Infarction, or Stroke — 153; 163 participants — p=0.15

Primary: Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation 6 Hours After Prasugrel Loading Dose (LD) — 57.86; 35.61; 53.92 PRU — p=0.188

Primary: Mean Change From Baseline to Week 4 in P2Y12 Reaction Units During Period 1 — -18.2 P2Y12 reaction unit

Primary: Incidence of Cardiovascular Mortality and Morbidity — 0.034050; 0.032759 Event per Patient Years of Followup

Primary: Major Bleeding — 11.2; 8.4 Percent probability

Primary: The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke — 7.4; 6.1; 6.1 Percentage of patients — p=0.020

Primary: Percent Change From Baseline in High-density Lipoprotein C (HDL-C) Levels After 4 Weeks of Treatment — 43.8; 10.1 Percentage raise in HDL-C Levels

Primary: Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 30 Days Post-percutaneous Coronary Intervention (PCI) — 14.7; 15.7; 0.6; 0.6…

Primary: Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-mediated Platelet Aggregation (P2Y12 Reaction Units; PRU) Using the Accumetrics VerifyNow (VN) P2Y12 Assay at 4 Hours…